Alpha 2.0
Login Register
» Authors » Jorg Tschmelitsch

Jorg Tschmelitsch

Explore the profile of Jorg Tschmelitsch including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 2365
Followers 0
Related Specialties
General Surgery
Oncology
General Medicine
Top 10 Co-Authors
Cord Langner
Thomas Eberl
Karl Mrak
Michael Jagoditsch
Michael Gnant
Rainer Fietkau
Dietmar Ofner
Richard Greil
Claus Rodel
Josef Thaler
Published In
South Med J
Surg Oncol
Cancers (Basel)
Surg Oncol Clin N Am
Am J Surg
Affiliations
Soon will be listed here.
Recent Articles
1.
Does Total Neoadjuvant Therapy Impact Surgical Precision in Total Mesorectal Excision? A Nationwide Survey of the Experiences of Expert Surgeons
Jager T, Zitt M, Riss S, Presl J, Schredl P, Neureiter D, et al.
Cancers (Basel) . 2025 Jan; 17(2. PMID: 39858065
Background: The treatment of locally advanced rectal cancer (LARC) has steadily progressed over the past four decades, with recent focus shifting towards total neoadjuvant therapy (TNT). This survey aims to...
2.
Pre- and Postoperative Levels of Carcinoembryonic Antigen in Microsatellite Stable Versus Instable Colon Cancer: a Retrospective Analysis
Salas Campos D, Weihs D, Rosenkranz M, Langner C, Geigl J, Tschmelitsch J, et al.
J Gastrointest Cancer . 2022 Jun; 54(2):600-605. PMID: 35716336
Purpose: The prognosis of microsatellite stable (MSS) versus instable (MSI) tumors is an ongoing matter of debate, with differences in expression of carcinoembryonic antigen (CEA) in these two tumor subsets...
3.
INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial
Panes J, Bouma G, Ferrante M, Kucharzik T, Nachury M, de la Portilla de Juan F, et al.
Inflamm Bowel Dis . 2022 Jan; 28(11):1737-1745. PMID: 35099555
Background: The efficacy of a single administration of darvadstrocel (expanded allogeneic adipose-derived mesenchymal stem cells) for treating complex perianal fistulas in patients with Crohn's disease was demonstrated in a randomized,...
4.
The long-term influence of hospital and surgeon volume on local control and survival in the randomized German Rectal Cancer Trial CAO/ARO/AIO-94
Sprenger T, Beissbarth T, Sauer R, Tschmelitsch J, Fietkau R, Hohenberger W, et al.
Surg Oncol . 2020 Sep; 35:200-205. PMID: 32896776
Background: The association of treatment volume and oncological outcome of rectal cancer patients undergoing multidisciplinary treatment is subject of an ongoing debate. Prospective data on long-term local control and overall...
5.
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected
Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, et al.
Eur Surg . 2018 Dec; 50(4):160-166. PMID: 30559831
Background: In operable esophageal cancer patients, neoadjuvant therapy benefits only those who respond to the treatment. The • Pancho trial represents the first prospective randomized trial evaluating the relevance of...
6.
A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients
Piringer G, Fridrik M, Fridrik A, Leiherer A, Zabernigg A, Greil R, et al.
Support Care Cancer . 2017 Nov; 26(4):1345-1352. PMID: 29168033
Introduction: Despite advances in adjuvant chemotherapy, 20-30% of patients in stages II-III colorectal cancer will eventually relapse. Observational studies showed a reduction in relapse rate, colon cancer-specific mortality, and overall...
7.
Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study
Eisterer W, Piringer G, de Vries A, Ofner D, Greil R, Tschmelitsch J, et al.
Anticancer Res . 2017 May; 37(5):2683-2691. PMID: 28476845
Aim: To evaluate feasibility and safety of neoadjuvant chemotherapy with capecitabine, oxaliplatin and bevacizumab followed by concomitant standard chemoradiation and surgical resection in patients with high-risk locally advanced rectal cancer....
8.
Tumor size, tumor location, and antitumor inflammatory response are associated with lymph node size in colorectal cancer patients
Rossler O, Betge J, Harbaum L, Mrak K, Tschmelitsch J, Langner C
Mod Pathol . 2017 Feb; 30(6):897-904. PMID: 28233767
Lymph node size affects lymph node retrieval in surgical specimen and is used as criterion for pre-operative radiological estimation of metastatic disease. However, factors determining lymph node size remain to...
9.
Diverting ileostomy versus no diversion after low anterior resection for rectal cancer: A prospective, randomized, multicenter trial
Mrak K, Uranitsch S, Pedross F, Heuberger A, Klingler A, Jagoditsch M, et al.
Surgery . 2015 Dec; 159(4):1129-39. PMID: 26706610
Background: This study sought to determine whether a protective diverting ileostomy improves short-term outcomes in patients with rectal resection and colonic J-pouch reconstruction for low anastomoses. Criteria for the use...
10.
TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients
Kandioler D, Mittlbock M, Kappel S, Puhalla H, Herbst F, Langner C, et al.
EBioMedicine . 2015 Oct; 2(8):825-30. PMID: 26425688
We investigated the hypothesis that the varying treatment efficacy of adjuvant 5-fluorouracil (5FU) in stage III colon cancer is linked to the TP53 mutational status. ABCSG-90 was a prospective randomized...